References
1. Karlsen TH, Sheron N, Zelber-Sagi S, Carrieri P, Dusheiko G, Bugianesi E, et al. The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet. 2022;399(10319):61-116. Epub 2021/12/06. doi: 10.1016/S0140-6736(21)01701-3. PubMed PMID: 34863359.
2. Secretaría General de Sanidad y Consumo, Ministerio de Sanidad Servicios Sociales e Igualdad. Plan estratégico para el abordaje de la hepatitis C en el Sistema Nacional de Salud [Internet] 2015. Available from: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/plan_estrategico_hepatitis_C.pdf.
3. Olafsson S, Tyrfingsson T, Runarsdottir V, Bergmann OM, Hansdottir I, Bjornsson ES, et al. Treatment as Prevention for Hepatitis C (TraP Hep C) - a nationwide elimination programme in Iceland using direct-acting antiviral agents. Journal of internal medicine. 2018;283(5):500-7. Epub 2018/03/08. doi: 10.1111/joim.12740. PubMed PMID: 29512219.
4. Isfordink CJ, Brakenhoff SM, van Dijk M, van der Valk M, de Knegt RJ, Arends JE, et al. Hepatitis C elimination in the Netherlands (CELINE): study protocol for nationwide retrieval of lost to follow-up patients with chronic hepatitis C. BMJ Open Gastroenterol. 2020;7(1):e000396. Epub 2020/05/08. doi: 10.1136/bmjgast-2020-000396. PubMed PMID: 32377367; PubMed Central PMCID: PMC7199651.
5. Lazarus JV, Picchio CA, Byrne CJ, Crespo J, Colombo M, Cooke GS, et al. A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination. Seminars in liver disease. 2022;42(2):159-72. doi: 10.1055/a-1777-6112.
6. Pawlotsky JM, Ramers CB, Dillon JF, Feld JJ, Lazarus JV. Simplification of Care for Chronic Hepatitis C Virus Infection. Seminars in liver disease. 2020;40(4):392-402. Epub 2020/07/30. doi: 10.1055/s-0040-1713657. PubMed PMID: 32725611.
7. Ministerio de Sanidad Servicios Sociales e Igualdad. Guía de Cribado de la infección por el VHC 2020. Available from: https://www.sanidad.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/GUIA_DE_CRIBADO_DE_LA_INFECCION_POR_EL_VHC_2020.pdf.
8. Cuadrado A, Llerena S, Cobo C, Pallas JR, Mateo M, Cabezas J, et al. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm. Am J Gastroenterol. 2018;113(11):1639-48. doi: 10.1038/s41395-018-0157-x. PubMed PMID: 29946175.
9. Cabezas J, Llerena S, Mateo M, Alvarez R, Cobo C, Gonzalez V, et al. Hepatitis C Micro-Elimination beyond Prison Walls: Navigator-Assisted Test-and-Treat Strategy for Subjects Serving Non-Custodial Sentences. Diagnostics (Basel). 2021;11(5). Epub 2021/06/03. doi: 10.3390/diagnostics11050877. PubMed PMID: 34068955; PubMed Central PMCID: PMC8155928.
10. Cuadrado A, Cabezas J, Llerena S, Nieves Salceda JF, Fortea JI, Crespo-Facorro B, et al. Prevalence of hepatitis C in patients with non-affective psychotic disorders. Rev Esp Enferm Dig. 2020;112(7):550-4. Epub 2020/06/25. doi: 10.17235/reed.2020.7278/2020. PubMed PMID: 32579015.
11. Estevez Escobar M, Casado Martin M, Moreno Moraleda I, Jordan Madrid T, Molina Maldonado C, Vinolo Ubina C, et al. Experience in the treatment of hepatitis C with direct-acting antivirals in a foreign population at a high-immigration area. Rev Esp Enferm Dig. 2021;113(10):704-8. Epub 2021/04/29. doi: 10.17235/reed.2021.7830/2021. PubMed PMID: 33906366.
12. Burgui C, Martin C, Aguinaga A, Perez-Garcia A, Ezpeleta C, Castilla J. Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019. Rev Esp Enferm Dig. 2021;113(1):28-34. Epub 2020/11/20. doi: 10.17235/reed.2020.7000/2020. PubMed PMID: 33207891.
13. Perez Castano Y, Chouza Perez JM, Sanz Largo V, Almandoz Cortajarena E, Gomez Garcia A, Esandi Gonzalez FJ, et al. Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa. Rev Esp Enferm Dig. 2020;112(7):545-9. Epub 2020/06/25. doi: 10.17235/reed.2020.7194/2020. PubMed PMID: 32579013.
14. Morales-Arraez D, Hernandez-Bustabad A, Medina-Alonso MJ, Santiago-Gutierrez LG, Garcia-Gil S, Diaz-Flores F, et al. Telemedicine and decentralized hepatitis C treatment as a strategy to enhance retention in care among people attending drug treatment centres. Int J Drug Policy. 2021;94:103235. Epub 2021/04/11. doi: 10.1016/j.drugpo.2021.103235. PubMed PMID: 33838399.
15. Colom J, Torrens M, Rodriguez-Cejas A, Aguilar I, Alvarez-Crespo R, Armenteros L, et al. Certification program of Addiction Centres for hepatitis C virus elimination in Spain. HepCelentes Project. Adicciones. 2022;0(0):1743. Epub 2022/10/07. doi: 10.20882/adicciones.1743. PubMed PMID: 36200230.
16. AEHVE. Alianza para la eliminación de las hepatitis virales [Internet] [28 de octubre de 2022]. Available from: https://aehve.org.
17. Calleja JL, Aguilera A, Buti M, Crespo J, Garcia F, Jorquera F, et al. Ten steps to eliminating hepatitis C in hospitals. Nat Rev Gastroenterol Hepatol. 2022;19(8):481-3. Epub 2022/06/24. doi: 10.1038/s41575-022-00647-1. PubMed PMID: 35739353.
18. Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, et al. Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. Gastroenterologia y hepatologia. 2022. Epub 2022/10/19. doi: 10.1016/j.gastrohep.2022.09.009. PubMed PMID: 36257502.
19. Vegas JJ, Flores-Herrera J, Latasa P, Garrido-Estepa M. Reduction in hepatitis C-related hospitalizations after the implementation of the Strategic Plan for Tackling Hepatitis C in the Spanish National Health System: regional level differences. Journal of viral hepatitis. 2021. Epub 2021/02/19. doi: 10.1111/jvh.13491. PubMed PMID: 33599365.
20. Rodriguez-Tajes S, Dominguez A, Carrion JA, Buti M, Quer JC, Morillas RM, et al. Significant decrease in the prevalence of hepatitis C infection after the introduction of direct acting antivirals. J Gastroenterol Hepatol. 2020;35(9):1570-8. Epub 2020/01/21. doi: 10.1111/jgh.14984. PubMed PMID: 31957902.
21. Polaris Observatory HCVC. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study. Lancet Gastroenterol Hepatol. 2022;7(5):396-415. Epub 2022/02/19. doi: 10.1016/S2468-1253(21)00472-6. PubMed PMID: 35180382.
22. Ministerio de Sanidad Servicios Sociales e Igualdad. Informe del Ministerio de Sanidad del Estudio de Seroprevalencia de la Hepatitis C en población general En España, 2017-2018. 2019. Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/INFORME_INFECCION_VHC_ESPANA2019.pdf.
23. Llaneras J, Barreira A, Rando-Segura A, Domínguez-Hernández R, Rodríguez-Frías F, Campins M, et al. Clinical impact and cost-effectiveness of hepatitis C testing in an emergency department in Barcelona, Spain. Journal of Hepatology. 2022;77:S44. doi: 10.1016/S0168-8278(22)00498-6.
24. Rosato V, Kondili LA, Nevola R, Perillo P, Mastrocinque D, Aghemo A, et al. Elimination of Hepatitis C in Southern Italy: A Model of HCV Screening and Linkage to Care among Hospitalized Patients at Different Hospital Divisions. Viruses. 2022;14(5). Epub 2022/05/29. doi: 10.3390/v14051096. PubMed PMID: 35632837; PubMed Central PMCID: PMC9143022.
25. Picchio CA, Lens S, Hernandez-Guerra M, Arenas J, Andrade RJ, Crespo J, et al. Late presentation of chronic HBV and HCV patients seeking first time specialist care in Spain: a 2-year registry review. Scientific reports. 2021;11(1):24133. Epub 2021/12/19. doi: 10.1038/s41598-021-01885-0. PubMed PMID: 34921156; PubMed Central PMCID: PMC8683418.
26. Santos M, Protopopescu C, Delarocque-Astagneau E, Bourliere M, Petrov-Sanchez V, Di Beo V, et al. Late presentation for HCV care: Time to target people with diabetes and/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver Int. 2022;42(1):38-49. Epub 2021/09/15. doi: 10.1111/liv.15056. PubMed PMID: 34520614.
27. Kondili LA, Buti M, Riveiro-Barciela M, Maticic M, Negro F, Berg T, et al. Impact of the COVID-19 pandemic on hepatitis B and C elimination: An EASL survey. JHEP Rep. 2022;4(9):100531. Epub 2022/08/16. doi: 10.1016/j.jhepr.2022.100531. PubMed PMID: 35967191; PubMed Central PMCID: PMC9364666.
28. US Preventive Services Task Force. Draft Recommendation Statement: Hepatitis C Virus Infection in Adolescents and Adults: Screening. USPSTF Recommendations [Internet] 2019. Available from: https://www.uspreventiveservicestaskforce.org/uspstf/document/draft-recommendation-statement/hepatitis-c-screening.
29. Action Hepatitis Canada. Progress Towards Viral Hepatitis Elimination By 2030 In Canada: 2021 Report [Internet]. 2021.
30. The Canadian Network on Hepatitis C. Blueprint Writing Committee and Working Groups. Blueprint to inform hepatitis C elimination efforts in Canada 2019 [Oct, 28th, 2022]. Available from: https://www.canhepc.ca/sites/default/files/media/documents/blueprint_hcv_2019_05.pdf.
31. AASLD/IDSA. AASLD/IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Clinical Liver Disease. 2018;12(5):117-. doi: 10.1002/cld.791. PubMed Central PMCID: PMC6385934.
32. Kondili L, Quaranta M, Ferrigno L, Galli M, Andreoni M, Puoti M, et al. Eliminazione dell’epatite c cronica in Italia: strategie di screening gratuito. Not Ist Super Sanità. 2021;34(5):6.
33. Crespo J, Albillos A, Buti M, Calleja JL, Garcia Samaniego J, Hernandez Guerra M, et al. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Rev Esp Enferm Dig. 2019;111(11):862-73. Epub 2019/10/29. doi: 10.17235/reed.2019.6700/2019. PubMed PMID: 31657609.
34. Buti M, Domínguez-Hernández R, Casado M, Sabater E, Esteban R. El cribado y tratamiento del virus de la hepatitis C en población general española entre 20 y 79 años de edad es coste-efectivo. Gastrenterol Hepatol. 2018;41(SE1).
35. Crespo J, Cuadrado A, Perello C, Cabezas J, Llerena S, Llorca J, et al. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain. Journal of viral hepatitis. 2020;27(4):360-70. Epub 2019/11/23. doi: 10.1111/jvh.13238. PubMed PMID: 31755634.
36. Nicolas Perez D, Morales Arraez DE, Castilla Rodriguez I, Gutierrez Nicolas F, Diaz-Flores Estevez F, de Vera Gonzalez A, et al. Hepatitis C virus infection screening reduces mortality and is cost-effective independently of the intervention test. Rev Esp Enferm Dig. 2022. Epub 2022/03/15. doi: 10.17235/reed.2022.8609/2022. PubMed PMID: 35285662.
37. Llanos-Méndez A, Molina-Linde J, Cerezo-Hidalgo C, Márquez-Peláez S. Efectividad clínica, seguridad y evaluación económica del cribado poblacional de hepatitis C. Revisión sistemática [Internet] AETSA Evaluación de Tecnologías Sanitarias de Andalucía; Ministerio de Sanidad 2022. Available from: https://www.aetsa.org/download/AETSA_Cribado_VHC_DEF_WEB.pdf
38. Crespo J, Tejerina Puente A, Cuadrado A, Llerena S, Cabezas J, Grupo de Trabajo para la Eliminacion de la Hepatitis CeC. Strategy for the Elimination of Hepatitis C in Cantabria. Rev Esp Enferm Dig. 2020;112(7):565-70. Epub 2020/06/17. doi: 10.17235/reed.2020.7108/2020. PubMed PMID: 32543873.
39. Xunta de Galicia, Servizio Galego de Saúde. Estratexia para a Eliminación da Hepatite C como problema de Saúde Pública en Galicia 2022. Available from: https://www.sergas.es/Saude-publica/Documents/6927/Estratexia_eliminacion_hepatite_C_en_Galicia.pdf.
40. Consejería de Salud y Consumo de la Junta de Andalucía. Boletín Oficial de la Junta de Andalucía. Número 201 - Miércoles, 19 de octubre de 2022. Plan para la Eliminación de la Hepatitis C en Andalucía. 2022 [Octubre 2022]. Available from: https://www.juntadeandalucia.es/boja/2022/201/BOJA22-201-00048-16280-01_00269544.pdf.
41. Catlett B, Hajarizadeh B, Cunningham E, Wolfson-Stofko B, Wheeler A, Khandaker-Hussain B, et al. Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review. The Journal of infectious diseases. 2022;226(6):1005-21. Epub 2022/02/13. doi: 10.1093/infdis/jiac049. PubMed PMID: 35150578.
42. Forns X, Colom J, Garcia-Retortillo M, Quer JC, Lens S, Martro E, et al. Point-of-care hepatitis C testing and treatment strategy for people attending harm reduction and addiction centres for hepatitis C elimination. Journal of viral hepatitis. 2022;29(3):227-30. Epub 2021/11/23. doi: 10.1111/jvh.13634. PubMed PMID: 34806812; PubMed Central PMCID: PMC9299793.
43. Saludes V, Antuori A, Lazarus JV, Folch C, Gonzalez-Gomez S, Gonzalez N, et al. Evaluation of the Xpert HCV VL Fingerstick point-of-care assay and dried blood spot HCV-RNA testing as simplified diagnostic strategies among people who inject drugs in Catalonia, Spain. Int J Drug Policy. 2020;80:102734. Epub 2020/05/30. doi: 10.1016/j.drugpo.2020.102734. PubMed PMID: 32470849.